The Venture Codex

Participated · Equity · Aug 2024

XO Life develops "Brite," a global meta-platform that consolidates digital product and therapy support so pharma and medtech companies can provide patient information, monitoring and engagement in a single infrastructure. The company emphasizes scalability by enabling many therapies and markets to use one platform instead of separate apps for each medication. XO Life works with more than 40 pharmaceutical companies, including three of the world's top ten, and plans to position Brite as a consolidated offering in early 2025. It intends to invest the new funding in AI capabilities and in processes to simplify and speed pharma onboarding across entire portfolios. XO Life focuses on B2B relationships at the interface of patients, medical professionals and the pharmaceutical industry, where long sales cycles and regulatory requirements are prominent. The company is headquartered in Munich and is using successive funding rounds to move from platform build-out to international scaling across Europe.